Biogen Idec/Elan Tysabri Clears FDA; Promotion Will Focus On Monotherapy

Biogen Idec and Elan plan to promote the once-monthly multiple sclerosis therapy Tysabri primarily as first-line monotherapy to patients who have discontinued previous therapy